Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large drop in short interest in February. As of February 15th, there was short interest totalling 74,900 shares, a drop of 92.5% from the January 31st total of 993,200 shares. Based on an average daily volume of 397,700 shares, the days-to-cover ratio is currently 0.2 days. Approximately 3.7% of the company’s stock are short sold.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. StockNews.com initiated coverage on Aptose Biosciences in a research report on Tuesday. They set a “hold” rating on the stock. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Aptose Biosciences in a report on Wednesday, February 12th.

Aptose Biosciences Price Performance

Shares of APTO stock opened at $3.25 on Friday. The business has a fifty day moving average of $6.02 and a 200 day moving average of $8.91. Aptose Biosciences has a 1 year low of $3.11 and a 1 year high of $58.18. The firm has a market capitalization of $6.96 million, a price-to-earnings ratio of -1.09 and a beta of 0.88.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Bleichroeder LP purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned 4.15% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.